Literature DB >> 15471638

[Should adjuvant treatments (antiplatelet agents, anticoagulants, normovolaemic haemodilution and vasodilators) be used in cervicofacial and maxillofacial free flaps reconstructive surgery?].

D Péan1, C Béliard.   

Abstract

The ENT and maxillo-facial reconstruction with free flaps has become a standard. The objective of the adjuvant treatments is to limit failures (approximately 6%) related to ischaemia/reperfusion. French surgical centres use specific protocols depending on the surgeon. They used antiplatelet agent, anticoagulants, normovolemic hamodilution and vasodilators. Many experimental studies are available. However, there is no clinical study to recommend the use of antiplatelet agents (combination with heparin increase the risk of pre- and postoperative bleeding), of normovolemic hemodilution (pulmonary oedema) and of vasodilators. After analysis of one of the only prospective study, we propose the use of heparin following a deep vein thrombosis preventive protocol. Due to the limited number of the patients and difficulty to have homogenous series, it is impossible to draw new recommendations, even if ischemic preconditioning techniques offer new research horizons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471638     DOI: 10.1016/j.annfar.2004.07.003

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  2 in total

1.  Head and neck reconstruction using microsurgery: a 9-year retrospective study.

Authors:  G H Holom; H Seland; E Strandenes; P G Liavaag; S Lybak; S Løes; K Tornes; H N Vintertun
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-16       Impact factor: 2.503

2.  Head and neck reconstruction with free flaps: a report on 213 cases.

Authors:  Olivier Dassonville; Gilles Poissonnet; Emmanuel Chamorey; Jacques Vallicioni; François Demard; Joseph Santini; Mayeul Lecoq; Sophie Converset; Pouya Mahdyoun; Alexandre Bozec
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-10       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.